Real-world outcomes after pembrolizumab treatment for cervical cancer: Results from a university setting
Pembrolizumab is safe and effective for advanced and recurrent cervical cancer in a real-world population. For those with good performance, further study is needed to determine if prolonged complete responses are cures. PS should be considered when making treatment recommendations, as patients with poor PS may not experience the survival benefits shown in pivotal trials.
Authors
- Dong Wang (ORCID: https://orcid.org/0000-0002-5245-3074)
- L. Stewart Massad (ORCID: https://orcid.org/0000-0001-8486-9464)
- Rachel L Furuya (ORCID: https://orcid.org/0000-0001-8259-2983)
- Mary Mullen (ORCID: https://orcid.org/0000-0002-4393-1548)
- Katelin Boak
Institutions
- Gynecologic Oncology Group (US)
- Washington University in St. Louis (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1016/j.gore.2025.101921
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05